Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
TNKASE (tenecteplase) is a fibrinolytic agent approved in 2000 for acute myocardial infarction (AMI). It is a genetically engineered variant of tissue plasminogen activator (tPA) that converts plasminogen to plasmin to dissolve blood clots. The drug is administered intravenously as a rapid bolus injection.
Product approaching loss of exclusivity with moderate competitive pressure (30/100); team is likely in defensive/optimization mode rather than growth expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Tenecteplase (TNK) in the Treatment of Intracerebral Hemorrhage (ICH)
A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well
Intra-Arterial Tenecteplase to Improve the Microvascular Hemodynamics After Mechanical Thrombectomy
Intra-arterial Tenecteplase for Acute Medium Vessel Occlusion Stroke
Tenecteplase Before Interhospital Transfer for EVT in Acute Anterior Circulation LVO at 4.5-24 Hours
Worked on TNKASE at Roche? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moTNKASE offers limited career momentum given its LOE-approaching status and lack of linked job openings; roles focus on defense, cost optimization, and managed care negotiations rather than growth initiatives. This product is best suited for professionals seeking stable, mature-market experience in a specialized acute care setting.